{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05806814",
            "orgStudyIdInfo": {
                "id": "OU-SCC-EXCITE"
            },
            "organization": {
                "fullName": "University of Oklahoma",
                "class": "OTHER"
            },
            "briefTitle": "Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer",
            "officialTitle": "Pilot Trial to Investigate Immune Response to an Extended Course of Sipuleucel-T Immunotherapy in Patients With Metastatic Castration-resistant Prostate Cancer (OU-SCC-EXCITE)",
            "acronym": "OUSCCEXCITE",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "sipuleucel-t-based-autologous-cellular-immunotherapy-for-advanced-prostate-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-11-12",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-11",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-11",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-03-28",
            "studyFirstSubmitQcDate": "2023-03-28",
            "studyFirstPostDateStruct": {
                "date": "2023-04-10",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-10",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-11",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "University of Oklahoma",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Dendreon",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "Proposed immunotherapy with an extended course of Sipuleucel-T treatment may induce a more robust immune response and improve the anti-cancer efficacy of Sipuleucel-T in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC).",
            "detailedDescription": "This open-label, pilot trial aims to evaluate the feasibility of Sipuleucel-T given in three doses at weeks 0, 2, and 12-14; and to investigate the changes in immune response in mCRPC patients who are getting an extended course of Sipuleucel-T treatment."
        },
        "conditionsModule": {
            "conditions": [
                "Metastatic Castration-Resistant Prostate Cancer (mCRPC)"
            ],
            "keywords": [
                "antigen presenting cells (APCs)",
                "Sipuleucel-T (Sip-T)",
                "granulocyte-macrophage colony-stimulating factor (GM-CSF)",
                "prostatic acid phosphatase (PAP)"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "The primary objective is to evaluate the feasibility and immune response of an extended course of Sipuleucel-T immunotherapy given at week 0, 2, and 12-14 in patients with metastatic castration-resistant prostate cancer.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 12,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Extended course of Sipuleucel-T treatment",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Biological: Sipuleucel-T"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "Sipuleucel-T",
                    "description": "Three doses of Sipuleucel-T, each containing a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, given at week 0, 2, and 12-14.",
                    "armGroupLabels": [
                        "Extended course of Sipuleucel-T treatment"
                    ],
                    "otherNames": [
                        "PROVENGE"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Proportion of patients completing 3 doses of Sipuleucel-T immunotherapy.",
                    "description": "Patients will be treated with Sipuleucel-T immunotherapy and the treatment regimen will be considered feasible if 85% of enrolled patients complete all three infusions of Sipuleucel-T treatment given at week 0, 2 and 12-14.",
                    "timeFrame": "up to 5 months"
                },
                {
                    "measure": "Proportion of subjects who have detectable elevated IgG level and/or T-cell proliferation from baseline to the follow-up of extended course of Sipuleucel-T immunotherapy.",
                    "description": "For patients undergoing Sipuleucel-T treatment on weeks 0, 2 and 12-14, the changes in immune response will be measured based on the detectable elevated levels of IgG and/or T-cell proliferation against various types of prostate cancer associated antigens at baseline, and at Sipuleucel-T infusion doses given at week 0, 2 and 12-14 weeks.",
                    "timeFrame": "up to 12 Months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Evaluate the mean difference in immune response to Sipuleucel-T treatment among different racial groups.",
                    "description": "Potential difference of immune response to Sipuleucel-T immunotherapy given at weeks 0, 2 and 12-14 will be compared in patients with mCRPC of different racial groups using the one-way ANOVA or the Kruskal-Wallis test.",
                    "timeFrame": "up to 12 months"
                },
                {
                    "measure": "Evaluate the potential tumor response based on the changes in serum PSA at baseline and within 30 days of last dose.",
                    "description": "For patients undergoing Sipuleucel-T treatment on weeks 0, 2 and 12-14, the preliminary tumor response will be measure through the comparison of serum PSA level between baseline and within 30 days of last dose.",
                    "timeFrame": "up to 12 Months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Men \u2265 18 years of age\n2. Prostate cancer with history of metastasis\n3. Candidates for Sipuleucel-T treatment are defined as those with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n5. Life expectancy of \u2265 6 months\n\nExclusion Criteria:\n\n1. Previously received Sipuleucel-T (Provenge\u00ae)\n2. Known malignancies other than prostate cancer likely to require treatment within 6 months following registration\n3. A requirement for systemic immunosuppressive therapy (\\>10mg Prednisone daily or equivalent)\n4. A history of allergic reactions attributed to compounds of similar chemical or biologic composition to Sipuleucel-T or GM-CSF\n5. Any infection requiring antibiotic therapy within 1 week prior to registration",
            "healthyVolunteers": false,
            "sex": "MALE",
            "genderBased": true,
            "genderDescription": "The study is focused on a prostate cancer-specific group.",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Lead Onco Nurse",
                    "role": "CONTACT",
                    "phone": "405-271-8777",
                    "email": "SCCIITOffice@ouhsc.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Kelly Stratton, MD",
                    "affiliation": "Investigator",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Stephenson's Cancer Center",
                    "status": "RECRUITING",
                    "city": "Oklahoma City",
                    "state": "Oklahoma",
                    "zip": "73114",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Kelly Stratton, MD",
                            "role": "CONTACT",
                            "phone": "405-271-6900",
                            "email": "Kelly-Stratton@ouhsc.edu"
                        },
                        {
                            "name": "Kelly Stratton, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.46756,
                        "lon": -97.51643
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011471",
                    "term": "Prostatic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005834",
                    "term": "Genital Neoplasms, Male"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000005832",
                    "term": "Genital Diseases, Male"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000011469",
                    "term": "Prostatic Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "asFound": "Prostate Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8946",
                    "name": "Genital Neoplasms, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8944",
                    "name": "Genital Diseases, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14333",
                    "name": "Prostatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M257633",
                    "name": "Molgramostim",
                    "relevance": "LOW"
                },
                {
                    "id": "M219218",
                    "name": "Sargramostim",
                    "relevance": "LOW"
                },
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}